ImageneBio (IMA) director receives 15,600 stock options at $5.45 strike

Rhea-AI Filing Summary

ImageneBio, Inc. director Bonita P. David received a grant of stock options covering 15,600 shares of Common Stock. The options have an exercise price of $5.45 per share and expire on June 16, 2036. They vest in full on the earlier of the first anniversary of the grant date, the company’s next annual meeting, or a change of control as defined in ImageneBio’s 2025 Equity Incentive Plan. Following this award, the filing shows David holding 15,600 options directly, with no open-market buying or selling reported.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Bonita David P

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	15,600	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 15,600 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 15,600 options Exercise price: $5.45 per share Expiration date: June 16, 2036 +2 more

5 metrics

Options granted 15,600 options Stock Option (right to buy) granted to director on June 16, 2026

Exercise price $5.45 per share Conversion or exercise price of stock options

Expiration date June 16, 2036 Option term under 2025 Equity Incentive Plan

Underlying shares 15,600 shares Common Stock underlying the derivative award

Holdings after grant 15,600 options Total derivative securities following transaction

Key Terms

Stock Option (right to buy), exercise price, change of control, 2025 Equity Incentive Plan

4 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

exercise price financial

"conversion_or_exercise_price: 5.4500"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

change of control financial

"the date of the Issuer's next annual meeting or a change of control"

A change of control occurs when the ownership or management of a company shifts significantly, such as through a sale, merger, or acquisition, resulting in new leadership or ownership structure. This change can impact the company's direction and decision-making, which is important for investors because it may affect the company's stability, strategy, and future prospects.

2025 Equity Incentive Plan financial

"as defined in the Issuer's 2025 Equity Incentive Plan"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bonita David P

(Last) (First) (Middle)

C/O IMAGENEBIO, INC.

12526 HIGH BLUFF DRIVE, SUITE 345

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ImageneBio, Inc. [ IMA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$5.45	06/16/2026		A		15,600		(1)	06/16/2036	Common Stock	15,600	$0	15,600	D

Explanation of Responses:

1. The shares vest in full upon the earlier to occur of the first anniversary of the date of grant, the date of the Issuer's next annual meeting or a change of control as defined in the Issuer's 2025 Equity Incentive Plan.

	/s/ Kristin Yarema, Attorney-in-Fact	06/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did ImageneBio (IMA) disclose about director Bonita P. David’s recent equity grant?

ImageneBio reported that director Bonita P. David received stock options for 15,600 shares of Common Stock at a $5.45 exercise price. These options are part of her board compensation and give her the right to buy shares if the options vest and are exercised.

How many ImageneBio (IMA) shares are covered by the new stock options?

The grant covers options on 15,600 shares of ImageneBio Common Stock. This entire 15,600-share amount is shown as held following the transaction, indicating the filing only reports this single new award for the director.

What is the exercise price and expiration date of the ImageneBio (IMA) options granted?

The options carry a $5.45 per share exercise price and expire on June 16, 2036. This means the director can choose to buy shares at $5.45 any time after vesting and before that expiration date, subject to plan terms.

When do Bonita P. David’s ImageneBio (IMA) stock options vest?

The options vest in full on the earliest of three events: the first anniversary of the grant date, ImageneBio’s next annual meeting, or a change of control as defined in the 2025 Equity Incentive Plan. Vesting must occur before the options can be exercised.

Did the ImageneBio (IMA) Form 4 show any open-market stock purchases or sales?

No open-market purchases or sales were reported. The Form 4 only shows a grant of stock options to director Bonita P. David as compensation, with 15,600 options acquired and no reported sales or exercises of Common Stock.